The distinction matters because early detection creates early intervention opportunities. A person might have excellent cholesterol numbers but still harbor silent Alzheimer’s pathology in their brain.
Conversely, someone with high cholesterol has a modifiable risk factor but no certainty they’ll develop dementia. The new blood tests can identify who actually has the disease process underway, allowing for lifestyle changes, medical monitoring, or future treatments to be targeted where they’ll have the most impact. Understanding this difference is essential for making informed choices about your preventive health care over the next decade.
Table of Contents
- Why Blood Biomarkers Detect Disease While Cholesterol Only Predicts Risk
- What the FDA Approval Actually Means (And What It Doesn’t)
- Cholesterol’s Link to Dementia—Why It Still Matters
- Who Can Get These Tests Today (And What to Expect)
- The Screening Gap—Why We’re Not Testing Everyone Yet
- How to Integrate Both Approaches Into Your Brain Health Strategy
- The Future of Dementia Screening—What’s Changing
- Conclusion
Why Blood Biomarkers Detect Disease While Cholesterol Only Predicts Risk
blood tests for Alzheimer’s and dementia work by measuring proteins that accumulate in the brain decades before cognitive symptoms appear. The most significant finding from recent research is that tau, phosphorylated tau, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) can predict dementia development with up to 83% accuracy in cognitively healthy older adults. This is particularly striking because these are asymptomatic people—they feel fine and perform normally on cognitive tests, yet the blood biomarkers reveal that disease processes are already active in their brains. In women specifically, these blood biomarkers can forecast dementia risk as many as 25 years before any cognitive decline appears. This predictive window is extraordinary and has no equivalent in cholesterol screening. By contrast, cholesterol screening identifies a risk factor for cardiovascular disease and, by extension, for dementia. High cholesterol is associated with increased dementia risk, and cholesterol-lowering drugs reduce dementia risk by up to 80% when targeting certain drug mechanisms. However, cholesterol screening doesn’t tell you whether disease is developing in your brain.
You might have perfect cholesterol and still have silent Alzheimer’s pathology. Or you might have high cholesterol but never develop dementia. Cholesterol is a risk modifier; blood biomarkers are disease indicators. For someone at age 40 or 45 trying to understand their personal brain health trajectory, the blood test offers information that cholesterol cannot: direct evidence of whether the disease process has begun. The practical implication is that blood biomarkers enable precision prevention in a way cholesterol screening does not. If your biomarkers show early Alzheimer’s pathology, you can pursue aggressive lifestyle modifications, regular monitoring, or future clinical trials of prevention medications. If your biomarkers are normal, you know you’re on a different trajectory. Cholesterol management is important for general cardiovascular health, but it’s a population-level risk reduction strategy, not a personalized disease indicator.
What the FDA Approval Actually Means (And What It Doesn’t)
In May 2025, the FDA approved the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio as the first blood test for Alzheimer’s disease detection, which was a watershed moment for early detection advocates. This test can identify Alzheimer’s disease with 88-92% accuracy in patients who have cognitive symptoms or cognitive concerns. However, there’s a critical limitation that shapes the current clinical landscape: this FDA-approved test is indicated for patients aged 55 and older with cognitive symptoms, not for asymptomatic screening in people over 40. This distinction is important and reflects where the evidence currently stands. The blood test has been studied and validated primarily in people who already have some cognitive concerns—memory problems, thinking difficulties, or other neurological symptoms that prompted their doctor to consider Alzheimer’s.
The research validating these tests in completely asymptomatic people is still emerging. Studies have shown that biomarkers can predict future cognitive decline in healthy people, but the clinical pathway for using these tests to screen entirely asymptomatic people under 55 has not yet been formally established by regulatory bodies or major medical organizations. For now, this means that if you’re 45 and cognitively normal, you typically can’t walk into your primary care doctor and request this specific FDA-approved test as a screening tool. The regulatory approval follows the evidence trail, and that trail is still being mapped for asymptomatic younger populations. However, the science suggesting these tests have predictive power in younger, cognitively healthy people is accumulating, and this landscape will almost certainly shift in the coming years.
Cholesterol’s Link to Dementia—Why It Still Matters
Before dismissing cholesterol as less important, it’s worth understanding its genuine role in dementia prevention. Research shows that drugs that lower LDL cholesterol reduce dementia risk by up to 80% for specific drug targets, which is a substantial protective effect. Additionally, a January 2025 study found that fluctuating cholesterol levels—how much your cholesterol goes up and down year to year—may actually be a better predictor of dementia risk than a single cholesterol measurement at one point in time. This finding suggests that cholesterol dynamics, not just absolute levels, matter for brain health. This research complicates the simple narrative that “cholesterol screening is old news.” Rather, it suggests that the relationship between cholesterol and dementia is more nuanced than previously understood.
Someone with stable, well-controlled cholesterol through diet and medication may be protecting their brain more effectively than someone whose cholesterol fluctuates wildly even if the average is acceptable. The implication is that cholesterol management—not just measurement, but active management to keep levels stable—contributes meaningfully to dementia prevention. However, cholesterol management is fundamentally different from disease detection. Lowering your cholesterol reduces your risk of dementia, but it doesn’t tell you whether you’ve already started down the path to cognitive decline. A person with excellent cholesterol control might still have silent Alzheimer’s pathology accumulating in their brain. This is why blood biomarkers and cholesterol screening address different questions: one asks “Am I already developing the disease?” and the other asks “What can I do to reduce my future risk?”.
Who Can Get These Tests Today (And What to Expect)
If you’re over 40 and want to understand your dementia risk, your options depend on your current health status and access to research or specialized care. If you have cognitive symptoms—memory lapses beyond normal aging, word-finding difficulties, getting lost in familiar places, or concerns from family members—you can discuss the FDA-approved blood tests with a neurologist or memory specialist. These clinicians have access to the Lumipulse G test and other validated blood biomarker panels, and they can order them as part of a diagnostic workup for cognitive concerns. If you’re cognitively normal but interested in predictive biomarkers, your options are currently more limited but expanding. Some major medical centers and specialized research institutions are offering blood biomarker testing through research protocols or advanced preventive medicine programs, but these aren’t yet standard-of-care offerings at most primary care clinics.
Clinical trials are ongoing that are evaluating blood biomarker screening in asymptomatic people, and participating in these studies is one way to access early testing. Additionally, as the science becomes clearer and more standardized, commercial labs are beginning to offer dementia risk biomarker panels, though insurance coverage for asymptomatic screening is inconsistent. For everyone over 40, cholesterol screening remains readily accessible through standard primary care. Getting your cholesterol checked, understanding your numbers, and working with your doctor on management—whether through diet, exercise, or medication—is straightforward and evidence-based. The combination approach would be: manage your cholesterol proactively now through accessible standard care, and revisit dementia-specific blood biomarker testing in a few years as the clinical recommendations for asymptomatic screening evolve.
The Screening Gap—Why We’re Not Testing Everyone Yet
A reasonable question is: if blood biomarkers can predict dementia decades in advance, why isn’t everyone over 40 getting tested? The answer involves clinical evidence standards, implementation logistics, and ethical considerations. Blood biomarkers for dementia haven’t yet been recommended for routine clinical screening of asymptomatic people without cognitive symptoms. This isn’t because the science isn’t promising—the predictive accuracy of 83% in healthy older adults is genuinely impressive—but rather because moving a test from research to population-wide screening requires additional evidence and infrastructure. First, there’s the question of clinical utility. Does knowing your dementia risk biomarkers change what an asymptomatic person does? For cognitive symptoms, the answer is yes: tests guide diagnosis and inform treatment options. But for a 45-year-old with normal cognition, the clinical pathway is less clear.
We know biomarkers predict future risk, but we don’t yet have definitive data on which lifestyle interventions, preventive medications, or monitoring schedules are most effective specifically for people identified by biomarker testing. Without that evidence, recommending widespread testing would be premature. Second, there are practical implementation challenges. Widespread biomarker screening would require training primary care providers to order and interpret these tests, ensuring access to specialized labs, and addressing insurance and cost issues. A positive biomarker result in an asymptomatic person could create anxiety without clear next steps, and that psychological impact needs to be managed thoughtfully. Additionally, some of these biomarker tests are still relatively expensive and not universally covered by insurance, creating equity issues if screening becomes recommended.
How to Integrate Both Approaches Into Your Brain Health Strategy
Rather than viewing blood biomarkers and cholesterol screening as competing priorities, they’re best understood as complementary components of a comprehensive dementia prevention strategy. Here’s a practical framework: Start with what’s accessible now—optimize your cholesterol management through standard primary care. Get your cholesterol checked, understand whether you have risk factors like high LDL or low HDL, and work with your doctor on interventions. Maintain stable cholesterol levels through a heart-healthy diet, regular exercise, and medication if needed. This addresses one well-established pathway to dementia risk reduction. Simultaneously, stay informed about developments in blood biomarker testing and begin conversations with your healthcare provider about whether you might be a candidate for testing. If you have any cognitive concerns—even subtle ones that might not yet meet the threshold for a diagnosis—ask about dementia biomarker testing sooner.
If you’re cognitively normal, discuss whether your doctor has recommendations for when you might consider biomarker testing, perhaps in a few years when testing becomes more standardized and accessible for asymptomatic people. Many memory specialists and preventive medicine physicians are already incorporating these tests into comprehensive brain health assessments. The combined approach recognizes that dementia prevention is multifactorial. Cholesterol management addresses one pathway. Blood biomarkers provide early detection. Both matter. A person might benefit from aggressive cholesterol management to modify risk factors, and simultaneously benefit from knowing their biomarker status to understand their disease trajectory. The goal is precision health—using multiple sources of information to tailor prevention strategies to your individual biology.
The Future of Dementia Screening—What’s Changing
The landscape for dementia blood biomarker screening is shifting rapidly. The FDA approval of the Lumipulse G test in 2025 was only the beginning. Additional blood biomarker tests are in development or regulatory review, and the validation of these tests in younger, asymptomatic populations is accelerating. It’s reasonable to expect that within the next 3-5 years, clinical recommendations will expand to include biomarker screening for asymptomatic people at higher risk, possibly including those over 40 with family histories of dementia or other risk factors.
Simultaneously, the science on interventions specifically targeted to biomarker-positive asymptomatic individuals is advancing. Ongoing clinical trials are testing whether early treatment with emerging Alzheimer’s drugs can delay or prevent cognitive decline in people identified by biomarkers before they develop symptoms. If these trials show positive results, the entire rationale for widespread biomarker screening becomes stronger—because early detection could lead to early treatment. That convergence of better screening, validated interventions, and clearer clinical pathways will reshape how we think about dementia prevention. The new dementia blood tests represent the beginning of this transformation, not its final form.
Conclusion
The new blood tests for dementia represent a meaningful advancement in our ability to understand individual brain health risk, offering predictive accuracy of up to 83-92% and the potential to identify disease processes 25 years before symptoms appear. For people over 40 concerned about cognitive health, these tests offer something cholesterol screening cannot: direct information about whether Alzheimer’s pathology is already developing in your brain. However, this doesn’t make cholesterol screening obsolete. Cholesterol management, particularly maintaining stable cholesterol levels, reduces dementia risk by up to 80% through proven biological pathways.
The most effective approach recognizes these as complementary strategies addressing different aspects of brain health. The current landscape requires a both/and perspective rather than either/or. Pursue accessible cholesterol management now through your primary care provider, establish stable heart-healthy patterns, and stay engaged with your healthcare team about emerging blood biomarker testing options. In the coming years, as clinical recommendations evolve and these tests become more widely available for asymptomatic screening, you’ll be well-positioned to make informed decisions about incorporating them into your personalized prevention strategy. Both strategies—cholesterol management and blood biomarker monitoring—will likely play important roles in reducing your dementia risk as the science continues to advance.
